Herbreteau Guillaume, Vallée Audrey, Charpentier Sandrine, Normanno Nicola, Hofman Paul, Denis Marc G
Department of Biochemistry, Nantes University Hospital, 9 quai Moncousu, F-44093 Nantes Cedex, France.
Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, "Fondazione G. Pascale", Naples, Italy.
J Thorac Dis. 2019 Jan;11(Suppl 1):S113-S126. doi: 10.21037/jtd.2018.12.18.
Major advances in the treatment of non-small cell lung cancer (NSCLC) patients have been obtained during the last decade. Molecular testing of tumor samples is therefore mandatory in routine clinical practice. Tumor DNA is also present as cell-free molecules in blood, which is therefore a very useful and convenient source of tumor DNA. In this review, we discuss pre-analytical and analytical aspects of circulating tumor DNA (ctDNA) analysis. We also describe the use of ctDNA analysis in routine clinical practice, and discuss the potential use of ctDNA monitoring both to identify minimal residual disease and as a potential tool to early identify patients' response to treatment.
在过去十年中，非小细胞肺癌（NSCLC）患者的治疗取得了重大进展。因此，肿瘤样本的分子检测在常规临床实践中是必不可少的。肿瘤DNA也以游离分子的形式存在于血液中，因此血液是肿瘤DNA非常有用且方便的来源。在本综述中，我们讨论了循环肿瘤DNA（ctDNA）分析的分析前和分析方面。我们还描述了ctDNA分析在常规临床实践中的应用，并讨论了ctDNA监测在识别微小残留病以及作为早期识别患者治疗反应的潜在工具方面的潜在用途。
